Aileron Therapeutics analyst ratings
Aileron Therapeutics analyst ratings
While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aileron Therapeutics (ALRN) is trading at is $0.28, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/29/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 06/05/2020 | 620.46% | HC Wainwright & Co. | $3 → $2 | Maintains | Buy |
| 03/31/2020 | 980.69% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 04/09/2019 | 1701.15% | Canaccord Genuity | $19 → $5 | Maintains | Buy |
| 03/11/2019 | 2421.61% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 07/24/2017 | 7104.61% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 07/24/2017 | 6744.38% | B of A Securities | → $19 | Initiates Coverage On | → Buy |
| 07/24/2017 | 6744.38% | Canaccord Genuity | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 06/29/2022 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 2020 年 5 月 6 日 | 620.46% | HC Wainwright & Co. | 3 美元 → 2 美元 | 维护 | 买 |
| 2020 年 3 月 31 日 | 980.69% | HC Wainwright & Co. | 6 美元 → 3 美元 | 维护 | 买 |
| 2019 年 9 月 4 日 | 1701.15% | Canaccord Genu | 19 美元 → 5 美元 | 维护 | 买 |
| 2019 年 11 月 3 日 | 2421.61% | HC Wainwright & Co. | → 7 美元 | 启动覆盖范围开启 | → 购买 |
| 07/24/2017 | 7104.61% | 杰富瑞集团 | → 20 美元 | 启动覆盖范围开启 | → 购买 |
| 07/24/2017 | 6744.38% | B of A 类证券 | → 19 美元 | 启动覆盖范围开启 | → 购买 |
| 07/24/2017 | 6744.38% | Canaccord Genu | → 19 美元 | 启动覆盖范围开启 | → 购买 |
Aileron Therapeutics Questions & Answers
Aileron Therapeutics 问题与解答
The latest price target for Aileron Therapeutics (NASDAQ: ALRN) was reported by William Blair on June 29, 2022. The analyst firm set a price target for $0.00 expecting ALRN to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
威廉·布莱尔于2022年6月29日公布了Aileron Therapeutics（纳斯达克股票代码：ALRN）的最新目标股价。该分析公司将目标股价定为0.00美元，预计ALRN将在12个月内降至12个月内（可能下跌-100.00％）。1家分析公司去年公布了评级。
The latest analyst rating for Aileron Therapeutics (NASDAQ: ALRN) was provided by William Blair, and Aileron Therapeutics downgraded their market perform rating.
威廉·布莱尔提供了Aileron Therapeutics（纳斯达克股票代码：ALRN）的最新分析师评级，Aileron Therapeutics下调了其市场表现评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aileron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aileron Therapeutics was filed on June 29, 2022 so you should expect the next rating to be made available sometime around June 29, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Aileron Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Aileron Therapeutics的最新评级是在2022年6月29日公布的，因此您应该预计下一个评级将在2023年6月29日左右公布。
While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aileron Therapeutics (ALRN) is trading at is $0.28, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Aileron Therapeutics（ALRN）评级已下调，目标股价为0.00美元至0.00美元。Aileron Therapeutics（ALRN）目前的交易价格为0.28美元，超出了分析师的预期区间。
